California’s State-Branded Insulin: A Risky Gamble That Could Backfire on American Patients

California’s ambitious plan to sell state-branded insulin starting January may appear as a beacon of hope for Americans struggling with soaring drug prices. Yet beneath the surface lies a deeper story highlighting the dangers of government-led market intervention and political theater masquerading as healthcare progress.Governor Gavin Newsom’s announcement marks nearly three years since his initial promise to offer lower-cost generics under the "CalRx" initiative. While the $11 per insulin pen price tag is eye-catching next to soaring market prices—such as Eli Lilly’s Rezvoglar selling for over $88 per five-pack—it is essential to question the sustainability and broader impact of this...